Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis, originally developed by repeated subculture to reduce virulence[7]. It is the only vaccine approved worldwide for the prevention of tuberculosis, particularly severe forms such as infant meningitis and miliary TB[3][5]. BCG is also used as a first-line immunotherapeutic agent for non-muscle invasive bladder cancer, where it is instilled intravesically to activate local immune responses and reduce tumor recurrence[3][5]. BCG's protective efficacy in tuberculosis varies among substrains - resulting from historical genetic differences - and it can trigger robust innate and adaptive immune responses[1][4]. Intradermal or mucosal administration leads to local infection and immunological activation, mainly through recognition by antigen-presenting cells and stimulation of T-cell mediated immunity[4]. BCG is also exploited as a recombinant bacterial vector for novel vaccine development targeting other infectious or neoplastic diseases[3][2]. The main safety challenges include potential for disseminated infection in immunosuppressed individuals and variable efficacy depending on substrain and dosing[1][5]. The correct canonical target is the vaccine organism itself (Bacillus Calmette-Guérin), not a molecular target such as an enzyme, receptor, or transporter. If structured data is desired for drug targets at the molecular level, BCG should not be classified alongside genes/proteins but as a live attenuated vaccine organism.
Induces strong cell-mediated immunity, predominantly T helper 1 (Th1) type response. Activation of innate immunity (macrophages, dendritic cells, monocytes via pattern recognition receptors like TLR2, TLR4, TLR9). Promotes production of cytokines (IL-2, IFN-γ, TNF-α, IL-12). Direct local immune activation and stimulation of antitumor responses in the bladder wall.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacillus Calmette-Guérin (live attenuated Mycobacterium bovis) (BCG).